NCT07005310

Brief Summary

The aim of this study is to perform a comparative analysis of clinical outcomes associated with the use of an ultra-long peripheral catheter using (catheter-over-the-needle technique) versus an AST-long peripheral catheter in adult patients with difficult intravenous access (DIVA) in a real-world clinical setting. Specifically, the study will assess potential benefits, including longer mean catheter dwell time and improved catheter usability, as well as potential harms, such as increased incidence of catheter-related thrombosis, infections, phlebitis, infiltration, and unplanned catheter removal.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 14, 2025

Completed
22 days until next milestone

First Posted

Study publicly available on registry

June 5, 2025

Completed
26 days until next milestone

Study Start

First participant enrolled

July 1, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2026

Completed
Last Updated

June 5, 2025

Status Verified

June 1, 2025

Enrollment Period

10 months

First QC Date

May 14, 2025

Last Update Submit

June 2, 2025

Conditions

Keywords

Long peripheral catheterAccelerated seldinger techniquePragmatic randomized controlled trialDwell timecomplications

Outcome Measures

Primary Outcomes (1)

  • Dwell time

    is defined as the duration between the date of catheter insertion and the date of its removal, expressed in hours.

    Until study completion, an average of 14 days.

Secondary Outcomes (5)

  • Number of Participants with Catheter related thrombosis

    Until study completion, an average of 14 days.

  • Number of Participants with Midline catheter related infections

    Until study completion, an average of 14 days.

  • Number of Participants with Phlebitis

    Until study completion, an average of 14 days.

  • Number of Participants with Loss of catheter usability

    Until study completion, an average of 14 days.

  • Number of Participants with Unplanned removal

    Until study completion, an average of 14 days.

Study Arms (2)

Accelerated seldinger technique LPC

ACTIVE COMPARATOR

One study arm will be assigned the AST-long peripheral catheter (Powerglide Pro long peripheral catheter, BD) available in 18G 100 mm, 20G 100 mm (approx. 3.94 inches) and 22G 80 mm (approx. 3.15 inches).

Device: Powerglide pro™

Ultra-long peripheral catheter

EXPERIMENTAL

The other study arm will be assigned the ultralong peripheral catheter (Introcan Safety deep access catheter, B. Braun) available in 18, 20 and 22G and 63.5 mm (approx. 2.5 inches) in length.

Device: Introcan safety deep access

Interventions

A long peripheral catheter will be placed under ultrasound guidance. This catheter will be placed by using the Accelerated seldinger technique.

Accelerated seldinger technique LPC

The catheter will be placed using ultrasound guidance and by using the 'catheter-over-the needle' approach.

Ultra-long peripheral catheter

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult inpatients with DIVA, requiring placement of a long peripheral catheter, will be included in the study.
  • A digital request form for venous access must be completed by the treating physician at the ward.
  • Patients must be proficient in either Dutch or French
  • Patients must have decision-making capacity or be represented by a legal representative.

You may not qualify if:

  • Expected therapy duration of less than 24 hours
  • pregnancy
  • Need for central venous access
  • Inability to locate a deep peripheral vein in the upper extremity prior enrollment in the study
  • Veins located deeper than 1.6cm prior enrollment in the study
  • withdrawal of consent, or presentation at a time when study personnel are unavailable.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universitair ziekenhuis Brussel

Brussels, Jette, 1090, Belgium

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr.

Study Record Dates

First Submitted

May 14, 2025

First Posted

June 5, 2025

Study Start

July 1, 2025

Primary Completion

April 30, 2026

Study Completion

April 30, 2026

Last Updated

June 5, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

The data is confidential.

Locations